Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma
Management of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.
Factors Identified for Risk of Second Cancer in CLL Following BTK Inhibition
David Bond, MD, discusses 2 key findings from a recent study investigating the risk of developing a second cancer in patients with chronic lymphocytic leukemia treated with a BTK inhibitor.